NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.…
Novocure Announces Upcoming Investor Events
NovoCure (NASDAQ: NVCR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 1,605 employees.
The shares were at 10.71 USD on 20 November 2026, down 5.7% over 52 weeks. Its 52-week range is 9.820 USD to 21.45 USD: the price is 50.1% below the high and 9.1% above the low.
Its market capitalisation is 1.25B USD.
NovoCure reports return on equity of -40.0%, an operating margin of -16.4% and revenue up 15.7% year over year.
It holds more cash than debt, a net cash position of 231.93M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 7 analysts cover the stock, with an average rating of Buy; their mean price target of 26.14 USD is 144.1% above the current price. The next earnings report is expected on 25 February 2027.